FindTrial
Sign In

ZEN003694

DRUG8 trials

Sponsors

Zenith Epigenetics, Alexander B Olawaiye, MD, Memorial Sloan Kettering Cancer Center, Haider Mahdi

Conditions

Fallopian Tube CancerMetastatic Castration-Resistant Prostate CancerOvarian CancerPeritoneal CancerRecurrent Solid TumorsSquamous Cell Lung CancerTriple Negative Breast CancermCRPC

Phase 1

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
CompletedNCT02705469
Zenith EpigeneticsMetastatic Castration-Resistant Prostate Cancer
Start: 2016-05-31End: 2017-10-31Target: 44Updated: 2017-11-20
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
CompletedNCT02711956
Zenith EpigeneticsMetastatic Castration-Resistant Prostate Cancer
Start: 2016-12-31End: 2019-11-30Updated: 2021-11-30
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Enrolling by invitationNCT04145375
Zenith EpigeneticsmCRPC
Start: 2019-11-12End: 2027-12-31Target: 40Updated: 2026-05-08
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
WithdrawnNCT06161493
Haider MahdiOvarian Cancer, Recurrent Solid Tumors
Start: 2024-01-23End: 2029-12-31Updated: 2024-10-15

Phase 2

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
TerminatedNCT03901469
Zenith EpigeneticsTriple Negative Breast Cancer
Start: 2019-06-26End: 2024-03-07Updated: 2025-10-07
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
RecruitingNCT04986423
Zenith EpigeneticsMetastatic Castration-Resistant Prostate Cancer
Start: 2021-09-08End: 2027-06-01Target: 200Updated: 2026-05-08
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RecruitingNCT05071937
Alexander B Olawaiye, MDFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Start: 2023-04-21End: 2034-12-31Target: 33Updated: 2026-06-18
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
RecruitingNCT05607108
Memorial Sloan Kettering Cancer CenterSquamous Cell Lung Cancer
Start: 2022-11-01End: 2027-11-01Target: 13Updated: 2026-03-11

Related Papers

A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2025-05-281 citations
A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.
Journal of Clinical Oncology2022-06-0120 citations
A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide.
Journal of Clinical Oncology2022-02-162 citations
Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.
2021-08-1225 citations
Abstract 1129: Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status
Cancer Research2021-07-011 citations
Abstract 1750: Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer
Cancer Research2020-08-15
Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Cancer Research2019-07-017 citations
Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Clinical Trials2019-07-012 citations
Abstract LB-038: Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients
Cancer Research2017-07-019 citations